Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-Label, First-In-Human, Multicenter Study of OP-1250 in Adult Subjects with Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer (Olema Pharmaceuticals OP-1250-001)

Study Details

OP-1250 is a small molecule Complete Estrogen Receptor ANtagonist (CERAN). OP-1250 potently competes with the endogenous activating estrogenic ligand 17-beta estradiol for binding in the ligand binding pocket. OP-1250 blocks estrogen-driven transcriptional activity, inhibits estrogen-driven breast cancer cell growth, and induces degradation of the estrogen receptor.

Learn More NCT number

Principal Investigators

  • Steve Lo, MD
Olema Pharmaceuticals
Mary Miller, LPN at 203-358-8879


  • Bennett Cancer Center
    One Hospital Plaza
    Stamford, CT 06902
    Main: 203-276-2695

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.